Lectures and seminars Faculty event: Jiangwei Sun and Fahim Ibrahim

07-05-2024 11:00 am Add to iCal
Campus Solna Wargentin lecture hall

Title: Heart failure in individuals with inflammatory bowel disease (Jiangwei) and Improving Outcomes in Patients with Liver Cancer (Fahim)

Speaker 1

Jiangwei Sun, a postdoctoral researcher in Jonas F. Ludvigsson's group. His research mainly focuses on the long-term health consequences in individuals with inflammatory bowel disease.

Title: Heart failure in individuals with inflammatory bowel disease


Dysregulation of inflammatory and immune responses have been implicated in the pathogenesis of heart failure (HF). But even if inflammation is a prerequisite for inflammatory bowel disease (IBD), little is known about HF risk in IBD. Until now, evidence from three existing studies is inconclusive. We therefore conducted a nationwide population-based cohort study to investigate the long-term risk of HF in individuals with IBD between 1969 and 2017 and followed them until December 2019.

Due to the compelling evidence for the increased cardiovascular risk in IBD and the contributing role of inflammation in HF, we hypothesized that individuals with IBD would be at an increased risk of HF.

Speaker 2

Fahim Ebrahimi, Postdoctoral researcher in Prof. Jonas F. Ludvigsson's group. I am a clinical researcher with background in endocrinology, gastroenterology and hepatology. My main research interests are Metabolic dysfunction-associated steatotic liver disease (MASLD) and liver cancer.

Topic: Improving Outcomes in Patients with Liver Cancer.


Liver cancer is the sixth most common cancer worldwide but the third leading cause of cancer-related mortality. It is characterized by substantial phenotypic and molecular heterogeneity, resulting in a considerable variability in the response to different treatment modalities. However, unlike other cancers, therapeutic decisions are primarily based on disease stage without consideration of molecular signatures, or prospectively evaluated predictive models. Hence, there is a huge unmet medical need for novel treatment strategies and for predictive tools to improve outcomes and to guide treatment decisions for patients with liver cancer. In this faculty seminar, I am going to present our grant application which includes an innovative investigator-initiated randomized controlled trial to investigate a novel treatment approach to improve outcomes in patients with liver cancer. 

Join the faculty event in Wargentin! After the seminar, faculty lunch will be served in Ljusgården.